Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02111096 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
NCT02111096 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 174 participants.
The verdict
NCT02111096, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
Study Summary
The intent of this study is to assess the safety of LY2409021 in participants with Type 2 diabetes mellitus taking metformin and sulfonylurea as prescribed by their personal physician. The study treatment is expected to last 12 months (52 weeks).
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Sitagliptin
- DRUG Sulfonylurea
- DRUG LY2409021
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02111096
The ClinicalTrials.gov registry entry for NCT02111096 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02111096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02111096 about?
NCT02111096 is a clinical study titled "A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus". The intent of this study is to assess the safety of LY2409021 in participants with Type 2 diabetes mellitus taking metformin and sulfonylurea as prescribed by their personal physician. The study treatment is expected to last 12 months (52 weeks).
What is the current status of trial NCT02111096?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2014-04. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02111096?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Sitagliptin (DRUG), Sulfonylurea (DRUG), LY2409021 (DRUG).
Who is sponsoring clinical trial NCT02111096?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.